Literature DB >> 2916384

Enzyme-immunoassay for estrogen receptors in human pituitary adenomas.

H Nakao1, M Koga, M Arao, M Nakao, B Sato, S Kishimoto, Y Saitoh, N Arita, S Mori.   

Abstract

We have performed an enzyme-immunoassay for estrogen receptor on 56 human pituitary adenomas and compared the results with a single point estradiol binding assay. There was a significant positive correlation between the two assays of cytoplasmic estrogen receptor (r = 0.960). Normal human pituitaries (N = 2) had an estrogen receptor concentration of 17 fmol/mg protein by enzyme-immunoassay. Of 14 prolactinomas, 6 (43%) contained estrogen receptor with a concentration of 33.5 +/- 7.4 (mean +/- SEM) fmol/mg protein. Six of 11 (55%) macroprolactinomas were estrogen receptor-positive, whereas all 3 microprolactinomas were estrogen receptor-negative. Only one (13%) of 8 GH- and PRL-secreting adenomas, and 3 of 6 (50%) gonadotropin-secreting adenomas were estrogen receptor-positive; the latter had a concentration of 13.5 +/- 1.6 fmol/mg protein. Estrogen receptor was not detected in 21 pure GH-secreting adenomas and 7 nonsecreting adenomas. These results demonstrate the precise frequency of estrogen receptor in various human pituitary adenomas, since enzyme-immunoassay as well as single point estradiol binding assay could detect estrogen receptor even in small specimens. Enzyme-immunoassay is suitable for evaluation of estrogen receptor status in human pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2916384     DOI: 10.1530/acta.0.1200233

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  9 in total

1.  Functional role of estrogen in pituitary tumor pathogenesis.

Authors:  Anthony P Heaney; Manory Fernando; Shlomo Melmed
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression.

Authors:  Anniina Raitila; Heli J Lehtonen; Johanna Arola; Elina Heliövaara; Manuel Ahlsten; Marianthi Georgitsi; Anu Jalanko; Anders Paetau; Lauri A Aaltonen; Auli Karhu
Journal:  Am J Pathol       Date:  2010-08-13       Impact factor: 4.307

Review 3.  Role of transcription factors in the pathogenesis of pituitary adenomas: a review.

Authors:  A Suhardja; K Kovacs; J Rutka
Journal:  J Neurooncol       Date:  2001-12       Impact factor: 4.130

Review 4.  Molecular determinants of pituitary cytodifferentiation.

Authors:  S L Asa; S Ezzat
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

5.  Estrogen receptors in prolactinomas: a clinico-pathological study.

Authors:  G J Kaptain; N E Simmons; T D Alden; M B Lopes; M L Vance; E R Laws
Journal:  Pituitary       Date:  1999       Impact factor: 4.107

6.  Pituitary corticotroph identity and receptor-mediated signaling: a transcriptomics perspective.

Authors:  Stanko S Stojilkovic; Rafael M Previde; Arthur S Sherman; Patrick A Fletcher
Journal:  Curr Opin Endocr Metab Res       Date:  2022-06-09

7.  Pituitary Sex Steroid Receptors: Localization and Function.

Authors:  Lucia Stefaneanu
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

Review 8.  Nuclear Receptors as Regulators of Pituitary Corticotroph Pro-Opiomelanocortin Transcription.

Authors:  Dongyun Zhang; Anthony P Heaney
Journal:  Cells       Date:  2020-04-07       Impact factor: 6.600

9.  Effects of resveratrol on cell growth and prolactin synthesis in GH3 cells.

Authors:  Wang Chao; Zhang Xuexin; Su Jun; Chu Ming; Jin Hua; Guofu Li; Chunlei Tan; Wanhai Xu
Journal:  Exp Ther Med       Date:  2014-02-13       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.